The value of new U.S. stock listings has only ticked up modestly from 2022, when rapidly rising interest rates and COVID-related distortions in some industries depressed IPO activity.
As of December 31, 2024. Source: Bloomberg Finance L.P.
Showing posts with label 2015 IPOs. Show all posts
Showing posts with label 2015 IPOs. Show all posts
Tuesday, December 31, 2024
Friday, November 15, 2024
vTv Therapeutics (VTVT) : 9-year performance
- Founded: 2015
- Headquarters: High Point, North Carolina
- Employees: 16
- vtvtherapeutics.com
Thursday, October 12, 2017
Zosano Pharma (ZSAN) : Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia
- zosanopharma.com
- Founded: 2006
- ZSAN IPO 1/27/15 at $11
Zosano Pharma Corp. (ZSAN) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM”) technology, announced today that Cephalalgia had published the Company’s positive results from our pivotal, multi-center, double blind, placebo controlled, trial demonstrating efficacy and safety of M207, our formulation of zolmitriptan using our ADAM technology.
ADAM is Zosano Pharma’s proprietary, investigational technology platform designed to offer rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. ADAM consists of an array of drug-coated titanium microprojections mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The microprojections penetrate the stratum corneum and allow drug to be absorbed into the microcapillary system of the blood.
Cephalalgia published a paper titled “Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Safety and Efficacy of ADAM Zolmitriptan for the Acute Treatment of Migraine”, which contained the positive results from Zosano’s ZOTRIP pivotal study. ZOTRIP was a multicenter, double-blind, randomized, placebo-controlled trial comparing three doses of M207 (1.0mg, 1.9mg, and 3.8mg) to placebo for the treatment of a single migraine attack. In this study of 365 migraineurs, the 3.8mg dose of M207 demonstrated a statistically significant benefit in both freedom from pain and freedom from a patient’s most bothersome symptom (photophobia, phonophobia or nausea and vomiting) at the 2 hour pre-specified primary endpoint. Secondary endpoints demonstrated pain freedom at 45 min after administration, with an effect that was sustainable for 48 hours post treatment. The majority of adverse events were mild or moderate application site reactions. There were no serious adverse events. Zosano announced the results of the ZOTRIP trial in February 2017.
“We are grateful for the contributions of our investigators, co-authors and advisors on the design, execution, analysis and reporting of the ZOTRIP trial,” said Dr. Don Kellerman, Vice President of Clinical Development. “We believe that the time from topline results to peer-reviewed publication in a prestigious journal reflects the design of the study and the unambiguous results.”
"We are pleased to have the results of ZOTRIP, our pivotal study, published in Cephalalgia," stated John P. Walker, Zosano’s Chairman and Chief Executive Officer. "The recognition of the results from ZOTRIP in such a well-known journal will continue to raise awareness of M207, and its ability to address an unmet need for patients struggling to find rapid and durable pain relief for migraine episodes.”
Monday, September 18, 2017
Nabriva Therapeutics (NBRV) : positive trial of pneumonia treatment
- www.nabriva.com
- HQ: Dublin, Ireland
- Founded in 2006
- IPO in 2015
- 59 Employees
********
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The company’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.
** charts before **
Friday, September 15, 2017
Neos Therapeutics (NEOS)
- Headquarters: Grand Prairie, TX
- Founded: 1994
- neostx.com
- IPO July 23, 2015; priced its IPO of 4.8M shares (up from 4M) of common stock at $15 per share.
The pharmaceutical firm develops products based on its proprietary modified-release drug delivery platform for the treatment of attention deficit hyperactivity disorder (ADHD). It currently markets only one product: a generic hydrocodone (narcotic cough suppressant) polistirex and chlorpheniramine (antihistamine) polistirex extended-release liquid suspension branded as Tussionex for the relief of cough and upper respiratory symptoms associated with allergy or cold in patients at least six years old.
Its three leading pipeline product candidates are: NT-0102, NT-0202 and NT-0201, all for the treatment of ADHD.
Neos Therapeutics receives U.S. FDA Approval of Adzenys ER (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older; to launch third medication in ADHD franchise in January 2018
*******
Description
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -380.40% | -910.35% |
| Operating margin | -333.69% | -847.64% |
| EBITD margin | - | -799.06% |
| Return on average assets | -68.92% | -82.24% |
| Return on average equity | -394.99% | -216.94% |
| Employees | 134 |
Thursday, May 4, 2017
Del Taco Restaurants (TACO) reported earnings Thur 4 May 2017 (a/h)
- IPO: June 30, 2015
** charts after earnings **
- Del Taco beats Street 1Q forecasts
The Lake Forest, California-based company said it had net income of 10 cents per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 9 cents per share.
The restaurant chain posted revenue of $105.3 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $105 million.
Del Taco expects full-year earnings to be 52 cents to 55 cents per share, with revenue in the range of $466 million to $476 million.
Del Taco shares have decreased 5 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $13.40, a rise of 35 percent in the last 12 months.
Tuesday, April 4, 2017
Benitec Biopharma (BNTC)
Ticker: BNTC
Benitec Biopharma announces that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications; studies demonstrate that a DNA directed RNA interference (ddRNAi) approach to 'silence and replace' the mutant PABPN1 protein:
- Co announces that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications, an open access scientific journal published by the Nature Publishing Group. OPMD, a rare progressive muscle-wasting disease caused by mutation in the poly-binding protein nuclear 1 gene, is characterised by eyelid drooping, swallowing difficulties, and proximal limb weakness.
- The key results from these studies demonstrate that a DNA directed RNA interference approach to 'silence and replace' the mutant PABPN protein, results in the correction of the muscular dystrophy and of key clinical features of OPMD including a progressive atrophy and muscle weakness associated with nuclear aggregates of insoluble PABPN1. These data were generated in the A17 mouse model that expresses the mutant PABPN1 gene and mimics most of the features of human OPMD patients.
Description
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.
Wednesday, August 3, 2016
Enviva Partners (EVA) reported earnings Wed 3 Aug 2016 (b/o)
- Div/yield 0.52/9.37
** charts before earnings **
** charts after earnings **
Enviva Partners beats by $0.05, misses on revs, updates FY16 guidance :
- Reports Q2 (Jun) earnings of $0.47 per share, $0.05 better than the two analyst estimate of $0.42; revenues rose 9.1% year/year to $119.7 mln vs the $123.17 mln Capital IQ Consensus.
- The Partnership updated its full-year 2016 guidance.
- The guidance amounts provided do not include the impact of any potential acquisitions from the Partnership's sponsor or others.
- The Partnership now expects full-year 2016 net income to be in the range of $40.0 million to $42.0 million, which reflects higher non-cash compensation expense and non-cash asset impairment and disposal charges than previously anticipated, and adjusted EBITDA to be in the range of $86.0 million to $88.0 million, which reflects the Partnership's better-than-expected performance during the first half of 2016.
- The Partnership expects to incur maintenance capital expenditures of $4.0 million and interest expense net of amortization of debt issuance costs and original issue discount of $12.0 million in 2016.
- The Partnership expects full-year distributable cash flow to be in the range of $70.0 million to $72.0 million, prior to any distributions attributable to incentive distribution rights paid to the general partner, which reflects the expected improvement in full-year adjusted EBITDA.
- For full-year 2016, they expect to distribute at least $2.10 per common and subordinated unit.
Thursday, December 10, 2015
Atlassian (TEAM) started trading on the Nasdaq on 10 December 2015
- Atlassian (TEAM) an enterprise software company, closed at $27.78 Thursday, up 32% from its issue price. The company had set an issue price of $21 Wednesday night, above its previously given range of $18 to $20. With the offering, the company said it was selling 22 million shares to raise $462 million. Volume was about 15 million shares, which was more than triple the average volume of the S&P 500 stocks, according to FactSet.
Thursday, December 3, 2015
Pure Storage (PSTG) reported earnings Thur 3 Dec 2015
** charts before earnings **
** charts after earnings **
Pure Storage beats by $0.13, beats on revs; sees Q4 revs above consensus :
Reports Q3 EPS of ($0.18) vs ($0.31) Capital IQ consensus; revs rose 167% YoY to $131.4 mln vs $107.4 mln consensus.
- Fourth Quarter Fiscal 2016 Guidance: Co sees revs in the range of $134-139 mln vs $122.9 mln consensus
Saturday, November 28, 2015
CytomX Therapeutics (CTMX) began trading on the NASDAQ on 8 Oct 2015
Address
343 Oyster Point Blvd., Suite 100
SOUTH SAN FRANCISCO, CA 94080
United States
SOUTH SAN FRANCISCO, CA 94080
United States
Website
http://cytomx.com/cyt01/Key stats and ratios
| Q2 (Jun '15) | 2014 | |
| Net profit margin | -214.10% | -597.01% |
| Operating margin | -271.27% | -586.27% |
| EBITD margin | - | -570.85% |
| Return on average assets | -17.43% | -69.48% |
| Return on average equity | - | - |
| Employees | 61 |
Description
CytomX Therapeutics, Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs, which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company's pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company's additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.
Subscribe to:
Posts (Atom)